BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TJ101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TJ101\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07181473-2768@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:TJ101: Phase 1 readout est. (NCT07181473)
DESCRIPTION:TJ101\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study t
 o Evaluate the Safety\, Pharmacokinetics and Efficacy of TJ101 in Patients
  With Advanced/Metastatic Solid Tumors\nEstimated primary completion: 30 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tj101#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07181
 473
URL:https://assetmemo.bio/drug/tj101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
